Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Antimicrob Agents Chemother ; 66(11): e0048322, 2022 11 15.
Article in English | MEDLINE | ID: mdl-36255258

ABSTRACT

Fluoroquinolone use in children is limited due to its potential toxicity and negative effects on skeletal development, but the actual effects/risks of fluoroquinolones on bone growth and the mechanisms behind fluoroquinolone-driven arthropathy remain unknown. Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic with a unique mechanism of action that is not anticipated to have the same risks to bone growth as those of fluoroquinolones. Gepotidacin is in phase III clinical development for uncomplicated urinary tract infections (ClinicalTrials.gov identifiers NCT04020341 and NCT04187144) and urogenital gonorrhea (ClinicalTrials.gov identifier NCT04010539) in adults and adolescents ≥12 years of age. To inform arthropathy and other potential toxicity risks of gepotidacin in pediatric studies, this nonclinical study assessed oral gepotidacin toxicity in juvenile rats from postnatal day (PND) 4 to PND 32/35 (approximately equivalent to human ages from newborn to 11 years), using both in-life assessments (tolerability, toxicity, and toxicokinetics) and terminal assessments (necropsy with macroscopic and microscopic skeletal femoral head and/or stifle joint examinations). Gepotidacin doses of ≤300 mg/kg of body weight/day were well tolerated from PND 4 to PND 21, and higher doses of ≤1,250 mg/kg/day were well tolerated from PND 22 when the dose levels were escalated to maintain systemic exposure levels up to PND 35, with no observed treatment-related clinical signs, effects on mean body weight gain, or macroscopic findings on articular surfaces. A dose of 1,000 mg/kg/day was not tolerated during the dosing period from PND 4 to 21, with effects on body weight gain, fecal consistency, and body condition. Microscopic effects on articular surfaces were evaluated after 32 days of gepotidacin treatment at the highest tolerated dose. After 32 days of treatment with the highest tolerated gepotidacin dose of 300/1,250 mg/kg/day (systemic concentrations [area under the curve {AUC} values] of 93.7 µg · h/mL [males] and 121 µg · h/mL [females]), no skeletal effects on articular surfaces of the femoral head or stifle joint were observed. The absence of treatment-related clinical signs and arthropathy in juvenile rats provides evidence to support the potential future use of gepotidacin in children.


Subject(s)
Joint Diseases , Polyketides , Adolescent , Adult , Animals , Child , Female , Humans , Male , Rats , Anti-Bacterial Agents/pharmacology , Body Weight , Fluoroquinolones , Microbial Sensitivity Tests , Topoisomerase II Inhibitors , Clinical Trials, Phase III as Topic
2.
Birth Defects Res B Dev Reprod Toxicol ; 86(6): 418-28, 2009 Dec.
Article in English | MEDLINE | ID: mdl-20025038

ABSTRACT

Assessment of potential developmental and reproductive toxicity of human pharmaceuticals is currently guided by the International Conference on Harmonization (ICH) S5(R2) document (available at http://www.ich.org). The studies that assess developmental hazard are generally conducted in rodents and rabbits. Based on the authors' collective experience, adequate designs (including range-finding studies) and the presentation of data for these studies are described in detail. In addition, the suggested initiation and then total duration of these studies in relation to clinical studies that enroll women of childbearing potential are described. Optional parameters that may be included in the studies are discussed, as are study designs that combine assessments of fertility and developmental toxicity. New methods that may replace or enhance current procedures are outlined. The details described herein will assist all laboratories performing these studies, individuals who need to plan for the studies, and regulatory agencies that ultimately review these studies.


Subject(s)
Abnormalities, Drug-Induced , Drug Evaluation, Preclinical , Drug-Related Side Effects and Adverse Reactions , Embryonic Development/drug effects , Fetal Development/drug effects , Toxicity Tests/methods , Animals , Animals, Inbred Strains , Female , International Agencies , International Cooperation , Male , Maternal Exposure , Mice , Rabbits , Rats , Research Design
3.
Birth Defects Res B Dev Reprod Toxicol ; 86(6): 429-36, 2009 Dec.
Article in English | MEDLINE | ID: mdl-20025039

ABSTRACT

Assessment of potential developmental and reproductive toxicity of human pharmaceuticals is currently guided by the ICH S5(R2) document, "Detection of Toxicity to Reproduction for Medicinal Products and Toxicity to Male Fertility." Studies that assess a candidate drug's effect on fertility are generally conducted in rats. The evolution of, and ultimate harmonization of, fertility study designs are reviewed, and specific elements of an acceptable design, as well as the recommendations for presentation of data, are described in detail. Additionally, the timing of nonclinical fertility studies in relation to clinical studies that enroll men and women of reproductive potential is reviewed. Possible strategies for combining fertility assessment with other study designs are also presented. This article provides testing laboratories, sponsors, and regulatory agencies with a comparison of current methods and designs, with the aim of providing a common understanding of the critical design features.


Subject(s)
Drug-Related Side Effects and Adverse Reactions , Fertility/drug effects , Research Design , Toxicity Tests/methods , Animals , Embryonic Development/drug effects , Female , International Agencies , International Cooperation , Male , Models, Animal , Rats , Risk Assessment , Time Factors
4.
Birth Defects Res B Dev Reprod Toxicol ; 83(4): 397-406, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18702118

ABSTRACT

BACKGROUND: The antimalarial, artesunate, is teratogenic and embryolethal in rats, with peak sensitivity on Days 10 and 11 postcoitum (pc). METHODS: We compared the developmental toxicity of structurally related artemisinins, dihdyroartemisinin (DHA), artemether (ARTM), and arteether (ARTE) to that of artesunate after oral administration to rats on Day 10 pc. In separate studies, embryolethality was characterized after single intravenous (IV) administration of artesunate on Day 11 pc, and toxicokinetic parameters following oral and IV administration were compared. Lastly, to determine whether maternal hematologic effects occurred at doses that affect embryonic erythroblasts, artesunate was orally administered on Day 11 pc at a dose that caused 100% embryolethality. RESULTS: All artemisinins caused the same pattern of embryolethality and fetal cardiovascular and skeletal abnormalities as previously shown for artesunate. In the IV study, marked postimplantation loss occurred at 1.5 and 3 mg/kg artesunate, but not at 0.75 mg/kg. Among the toxicokinetic parameters evaluated, only the DHA AUC(0-t) was similar at embryolethal oral and IV doses of artesunate. An embryolethal dose of artesunate caused a 15% decrease in maternal reticulocyte counts and no other hematologic effects. CONCLUSIONS: Several structurally related artemisinins cause similar developmental toxicity, suggesting an artemisinin class effect. Equally embryotoxic oral and IV treatments of one artemisinin compound (artesunate) produced similar systemic exposure to the artesunate metabolite, DHA, suggesting that DHA may be the proximate developmental toxicant. Embryolethal doses of artesunate only caused minor changes in maternal reticulocyte counts indicating that adult hematology parameters are not as sensitive as embryonic erythroblasts.


Subject(s)
Artemisinins/pharmacokinetics , Artemisinins/toxicity , Embryo, Mammalian/drug effects , Prenatal Exposure Delayed Effects/blood , Reticulocytes/drug effects , Administration, Oral , Animals , Artemether , Artemisinins/administration & dosage , Artemisinins/blood , Artesunate , Cesarean Section , Drug Administration Routes , Embryo Loss/chemically induced , Female , Fetus/drug effects , Injections, Intravenous , Pregnancy , Prenatal Exposure Delayed Effects/chemically induced , Rats , Reticulocyte Count , Reticulocytes/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...